Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis

Background. Noncystic fibrosis bronchiectasis (NCFB) is characterized by airway expansion and recurrent acute exacerbations. Macrolide has been shown to exhibit anti-inflammatory effects in some chronic airway diseases. Objective. To assess the efficacy of roxithromycin on airway inflammation and re...

Full description

Saved in:

Bibliographic Details
Published in:	Mediators of Inflammation Vol. 2014; no. 7; pp. 129 - 142
Main Authors:	Zhong, Dengjun, Zhong, Wei, Zhang, Jianquan, Zheng, Xiaozhen, Wei, Lianghong, He, Zhiyi, Zhong, Xiao-Ning, Liu, Jifeng, Bai, Jing
Format:	Journal Article
Language:	English
Published:	Cairo, Egypt Hindawi Limiteds 01-01-2014 Hindawi Publishing Corporation John Wiley & Sons, Inc Hindawi Limited
Subjects:	Adolescent Adult Aged Airway (Medicine) Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - pharmacology Antibiotics Bronchi - metabolism Bronchiectasis Collagen Collagen Type IV - metabolism Dosage and administration Drug interactions Female Health aspects Hospitals Humans Hyaluronoglucosaminidase - metabolism Identification and classification Inflammation Inflammation - drug therapy Inflammation - metabolism Interleukin-8 - metabolism Leukocyte Elastase - metabolism Male Matrix Metalloproteinase 9 - metabolism Middle Aged Neutrophils - metabolism Patients Physiological aspects Quality of Life Respiratory diseases Rodents Roxithromycin - pharmacology Survival analysis Tomography, X-Ray Computed Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background. Noncystic fibrosis bronchiectasis (NCFB) is characterized by airway expansion and recurrent acute exacerbations. Macrolide has been shown to exhibit anti-inflammatory effects in some chronic airway diseases. Objective. To assess the efficacy of roxithromycin on airway inflammation and remodeling in patients with NCFB under steady state. Methods. The study involved an open-label design in 52 eligible Chinese patients with NCFB, who were assigned to control (receiving no treatment) and roxithromycin (receiving 150 mg/day for 6 months) groups. At baseline and 6 months, the inflammatory markers such as interleukin- (IL-)8, neutrophil elastase (NE), matrix metalloproteinase- (MMP)9, hyaluronidase (HA), and type IV collagen in sputum were measured, along with the detection of dilated bronchus by throat computed tomography scan, and assessed the exacerbation. Results. Forty-three patients completed the study. The neutrophil in the sputum was decreased in roxithromycin group compared with control ( P < 0.0 5 ) . IL-8, NE, MMP-9, HA, and type IV collagen in sputum were also decreased in roxithromycin group compared with the control group (all P < 0.01 ) . Airway thickness of dilated bronchus and exacerbation were reduced in roxithromycin group compared with the control (all P < 0.0 5 ) . Conclusions. Roxithromycin can reduce airway inflammation and airway thickness of dilated bronchus in patients with NCFB.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 Academic Editor: Alex Kleinjan
ISSN:	0962-9351 1466-1861
DOI:	10.1155/2014/708608